BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31779982)

  • 1. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of FLT3 in AML: a focus on sorafenib.
    Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
    Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growing landscape of FLT3 inhibition in AML.
    Smith CC
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):539-547. PubMed ID: 31808872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
    Fathi AT; Chen YB
    Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Novatcheva ED; Anouty Y; Saunders I; Mangan JK; Goodman AM
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e161-e184. PubMed ID: 34649791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
    Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.